Stock Ticker

  • Loading stock data...

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Provides Positive Update on ProscaVax Data

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) has been one of our favorite new players in the $7.1 billion prostate cancer treatment market. The company just put out a new press release summarizing data that makes a strong case in the preparation of a coming Phase II trial of ProscaVax, which is OncBioMune’s lead pipeline asset. As noted […]

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Reports New Prostate Cancer Clinical Trial Results

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported long-term clinical study results from its NX-1207 Phase II prostate cancer trial NX03-0040. The new findings reflect statistically significant better results at up to 2.8 years for “NX-1207” treated patients as compared to controls. The study included 146 enrollments suffering with low-grade localized prostate cancer. The study was carried out […]

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4%

Boston, MA 07/17/2013 (wallstreetpr) – Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced favorable results from the recent review of Safety Monitoring Committee on the safety data in the study “NX02-0017” in one of the two ongoing phase 3 pivotal studies of “NX-1207” that is currently in the company’s pipeline for benign prostatic hyperplasia. The Safety Monitoring […]

Sign Up To Get Our Latest Stocks Alerts